Evommune, Inc. (EVMN)
NYSE NYSE Primary Summary
EVMN Stock Tanks as Phase IIb Urticaria Study Misses Primary Goal
Evommune shares fall after its phase IIb CSU study misses the primary endpoint, prompting the company to halt further development of EVO756 for the indication.
Evommune, Inc. (EVMN) Discusses Scientific Rationale and Pipeline Expansion for MRGPRX2 Antagonist in Migraine Prevention Transcript
Evommune, Inc. (EVMN) Discusses Scientific Rationale and Pipeline Expansion for MRGPRX2 Antagonist in Migraine Prevention Transcript
Evommune, Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 John H. Burbank III Passport Capital LLC | 847,390 | $19.48M | $10.2M | -$9.28M | -47.63% |
 Point72 Asset Management LP Point72 Asset Management LP | 36,577 | $639,071.06 | $441,850.16 | -$197,220.9 | -30.86% |
 Joseph Castro Nuveen LLC | 12,452 | $286,271 | $151,603.1 | -$134,667.9 | -47.04% |
| RO Regan O'Neill Burkehill Global Management LP | 50,000 | $856,000 | $619,000 | -$237,000 | -27.69% |
 Li Peng China Universal Asset Management Co. Ltd. | 5,000 | $103,210 | $62,200 | -$41,010 | -39.73% |
Evommune, Inc. (EVMN) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Evommune, Inc. ever had a stock split?
Evommune, Inc. Profile
| Biotechnology Industry | Healthcare Sector | Luis C. Pena CEO | NYSE Exchange | 30054Y107 CUSIP |
| US Country | 48 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Evommune, Inc. is a clinical-stage biotechnology company based in Palo Alto, California, that specializes in developing innovative therapies aimed at chronic inflammatory diseases. Established in 2020, the company has initiated several clinical development programs that specifically target chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. Evommune's mission is to address the underlying causes of these conditions, thus improving the quality of life for individuals suffering from these chronic ailments.
Products and Services
- EVO756: This product is designed for the treatment of Chronic Spontaneous Urticaria (CSU) and Atopic Dermatitis (AD). EVO756 works by targeting specific pathways involved in the inflammation and immune response associated with these conditions, potentially offering relief to patients dealing with the discomfort and challenges of these chronic skin disorders.
- EVO301: Intended for use in treating Atopic Dermatitis (AD) and Ulcerative Colitis (UC), EVO301 aims to modulate the immune system and reduce inflammation. This product represents Evommune’s commitment to developing advanced therapies that address not only the symptoms but also the root causes of persistent inflammatory diseases.
